VBI Vaccines

VBI Vaccines, Inc. is a biopharmaceutical company, which engages in the development of infectious disease and immuno-oncology vaccines. The firm focuses on the prevention and treatment of hepatitis B through its product pipeline, Sci-B-Vac and VBI-2601. It also develops an enveloped virus-like particle (eVLP) platform technology, which allows the development of eVLP vaccines that closely mimic the target virus to elicit a potent immune response. The company was founded on April 9, 1965 and is headquartered in Cambridge, MA.

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

VBI Vaccines, Inc. (VBIV) delivered earnings and revenue surprises of 7.14% and 6.67%, respectively, for the quarter ended June 2019.

VBI Vaccines, Inc. (VBIV) Reports Q2 Loss, Tops Revenue Estimates

VBI Vaccines, Inc. (VBIV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

Will VBI Vaccines, Inc. (VBIV) Report Negative Q2 Earnings?

VBI Vaccines plummeted this week despite data showing its HBV vaccine Sci-B-Vac outperforms GlaxoSmithKline's Engerix-B on almost all metrics.

Bull Case For VBI Vaccines Damaged, But Still Intact

CEO, President of Vbi Vaccines Inc (NASDAQ:VBIV) Jeff Baxter bought 144,000 shares of VBIV on 06/19/2019 at an average price of $0.73 a share.

Vbi Vaccines Inc (VBIV) CEO, President Jeff Baxter Bought $105,120 of Shares

VBI Vaccines Inc (NASDAQ: VBIV) shares were in penny stock territory Monday following the release of data from a late-stage study of its hepatitis B virus vaccine candidate.

VBI Shares Plunge On Mixed Late-Stage Hepatitis B Vaccine Trial Results

VBI Vaccines has been struggling lately, but the selling pressure may be coming to an end soon.

VBI Vaccines Sees Hammer Chart Pattern: Time to Buy?

VBI Vaccines, Inc. (VBIV) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

All You Need to Know About VBI Vaccines, Inc. (VBIV) Rating Upgrade to Buy

VBI Vaccines, Inc. (VBIV) delivered earnings and revenue surprises of 0.00% and 80.00%, respectively, for the quarter ended March 2019.

VBI Vaccines, Inc. (VBIV) Reports Q1 Loss, Tops Revenue Estimates

News for VBI Vaccines Stock (VBIV)